MIRA INFORM REPORT

Report Date :

31.08.2013

IDENTIFICATION DETAILS

Name :	FAMY CARE LIMITED
Registered Office :	12-14, 3^rdFloor, Brady House, Veer Nariman Road, Fort, Mumbai-400001, Maharashtra
Country :	India
Financials (as on) :	30.06.2012
Date of Incorporation :	28.09.1987
Com. Reg. No.:	11-044813
Capital Investment / Paid-up Capital :	Rs.17.073 Millions
CIN No.: [Company Identification No.]	U24236MH1987PLC044813
TAN No.: [Tax Deduction & Collection Account No.]	MUMF03740C
PAN No.: [Permanent Account No.]	AAACF1663R
Legal Form :	A Closely Held Public Limited Liability Company
Line of Business :	Manufacturing, Selling and Development of Pharmaceutical Products.
No. of Employees :	Not Available

RATING & COMMENTS

MIRA’s Rating :

A (59)

RATING		STATUS	PROPOSED CREDIT LINE
56-70	A	Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums	Fairly Large

Maximum Credit Limit :	USD 9520000
Status :	Good
Payment Behaviour :	Regular
Litigation :	Clear
Comments :	Subject is a well established and reputed company having a good track record. Financially company appears to be strong. Performance capability is high. Liquidity position is good. Trade relations are reported to be fair. Business is active. Payments are reported to be regular and as per commitments. The company can be considered for normal business dealings at usual trade terms and conditions.

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

ECGC Country Risk Classification List – March 31^st, 2013

Country Name	Previous Rating (31.12.2012)	Current Rating (31.03.2013)
India	A1	A1

Risk Category	ECGC Classification
Insignificant	A1
Low	A2
Moderate	B1
High	B2
Very High	C1
Restricted	C2
Off-credit	D

INDIAN ECONOMIC OVERVIEW

We are living in a world where volatility and uncertainty have become the New Normal. We saw a change of government in countries like Tunisia, Egypt, Libya and Vietnam. Once powerful countries in Europe are now fighting for bankruptcy. We have taken growth in the developing part of the world for granted but economic growth in China and India has begun to slow. Companies that were synonymous with their product categories just a few years ago are now no longer in existence. Kodak, the inventor of the digital camera had to wind up its operations, HMV, the British entertainment retailing company and Borders, once the second largest bookstore have shut down due to their inability to evolve their business models with the changing time. Readers’ Digest, Thomson Register are no more !

There is another megatrend happening. The World order is changing as economic power shifts from West to East. According to McKinsey study, it took Britain more than 100 years to double its economic output per person during its industrial revolution and the US later took more than 50 years to do the same. More than a century later, China and India have doubled their GDP per capital in 12 and 18 years respectively. By 2020, emerging Asia will become the world’s largest consuming block, overtaking North America.

The years after the outbreak of the global financial crisis, the world economy continues to remain fragile. The Indian economy demonstrated remarkable resilience in the initial years of the contagion but finally lost ground last year. GDP growth slowed down. Currency has been weakening. There is a marked deceleration in agriculture, industry and services. Dampening sentiment led to a cut-back in investment as well as private consumption expenditure.  Inflation remained at high levels fuelled by the pressure from the food and fuel sectors. The large fiscal and current account deficit s continued to cause grave concern. It is imperative that India regains its growth trajectory of 8-9 % sooner than later. This is crucially important given the need to create gainful livelihood opportunities for the millions living in poverty as also the large contingent of young people joining the job market every year.

EXTERNAL AGENCY RATING

Rating Agency Name	CRISIL
Rating	A+ [Long Term]
Rating Explanation	Having adequate degree of safety regarding timely servicing of financial obligation it carry low credit risk.
Date	12.11.2012

RBI DEFAULTERS’ LIST STATUS

Subject’s name is not enlisted as a defaulter in the publicly available RBI Defaulters’ list.

EPF (Employee Provident Fund) DEFAULTERS’ LIST STATUS

Subject’s name is not enlisted as a defaulter in the publicly available EPF (Employee Provident Fund) Defaulters’ list as of 31-03-2012.

LOCATIONS

Registered / Corporate Office :	12-14, 3^rdFloor, Brady House, Veer Nariman Road, Fort, Mumbai-400001, Maharashtra, India
Tel. No.:	91-22-30289655 / 30289636
Fax No.:	91-22-3028 9656
E-Mail :	ho@famycare.com prashant@famycare.com
Website :	www.famycare.com
Location :	Owned
Factory 1 :	Plot No. 1608 and 1609, G.I.D.C. Sarigam – 396 155 Gujarat, India
Tel. No.:	91-260-2780674, 2780502
Fax No.:	91-260-2780574
Factory 2 :	Plot No. 688/10/11, Siddhi Vinayak Industrial Estate, Opposite Somnath Temple, Somnath, Daman – 396 210, India
Tel. No.:	91-260- 224 2484, 224 3279
Fax No.:	91-260-224 3279
Factory 3 :	Plot No. L-20,Verna Industrial Estate, Salcette, Verna-403722, Goa, India
Overseas Office 1 :	PK 7 Route Da Cabassou Remire
Tel. No.:	91-594-230726
Fax No.:	91-594-290645
Overseas Office 2 :	Mar 26 Street, Ward 5, Go Vap District, HCM City
Tel. No.:	91-84-5880322

DIRECTORS

AS ON 11.12.2012

Name :

Mr. Sanjeev Jyotiprasad Taparia

Designation :

Managing Director

Address :

101/Laxmi Vilas, 10^th Floor, 87, Nepean Sea Road, Mumbai-400006, Maharashtra, India

Date of Birth/Age :

29.07.1967

Date of Appointment :

01.04.2011

Din No.:

00157770

Other Directorship :

S. No.	CIN/LLPIN	Name of the Company/ LLP	Current designation of the Director/ Designated Partner	Date of appointment at current designation	Original date of appointment	Date of cessation	Company/ LLP Status	Defaulting status
1	U01100MH1995PTC087948	SAROJ PLANTATIONS PRIVATE LIMITED	Director	28/09/1996	28/09/1996	-	Active	NO
2	U01100MH1995PTC087949	MAKARAND PLANTATIONS PRIVATE LIMITED	Director	28/09/1996	28/09/1996	-	Active	NO
3	U01100MH1995PTC087946	GYAN PLANTATIONS PRIVATE LIMITED	Director	28/09/1996	28/09/1996	-	Active	NO
4	U25202MH1995PTC088387	FAMY STERI PRIVATE LIMITED	Director	13/11/1996	13/11/1996	-	Active	NO
5	U27200MH1995PTC084250	SAI CYLINDERS PRIVATE LIMITED	Director	07/04/1997	07/04/1997	31/08/2010	Active	NO
6	U24232GA1997PTC002375	KENPACK PHARMA PRIVATE LIMITED	Director	04/07/1997	04/07/1997	-	Active	NO
7	U24236MH1987PLC044813	FAMY CARE LIMITED	Managing director	01/04/2011	10/09/1998	-	Active	NO
8	U51909MH2004PTC148478	PEEPAL TRADING AND AGENCIES PRIVATE LIMITED	Director	09/09/2004	09/09/2004	31/03/2008	Active	NO
9	U51909MH2004PTC148474	SILVA TRADING AND AGENCIES PRIVATE LIMITED	Director	09/09/2004	09/09/2004	31/03/2008	Active	NO
10	U24100GA2004PTC007040	ARYAVAAN PHARMACEUTICALS PRIVATE LIMITED	Director	29/09/2004	29/09/2004	16/03/2012	Active	NO
11	U45200MH2004PTC148885	SHUBH GRAH PRAVESH PRIVATE LIMITED	Director	29/09/2004	29/09/2004	-	Active	NO
12	L25200GJ1984PLC050560	GOPALA POLYPLAST LTD	Director	26/06/2006	26/06/2006	10/03/2008	Active	NO
13	U51909MH2006PTC165687	SANGUINITY TRADING COMPANY PRIVATE LIMITED	Director	27/12/2006	27/12/2006	-	Active	NO
14	U24232GA1997PTC002374	BEACH HEALTHCARE PRIVATE LIMITED	Director	06/08/2007	06/08/2007	-	Active	NO
15	U24139MH2004PTC144395	TARAKESH PHARMA PRIVATE LIMITED	Director	30/09/2009	05/08/2008	-	Active	NO
16	U25190MH1998PTC114824	HEVEA FINE PRODUCTS PRIVATE LIMITED	Director	28/09/2009	05/08/2008	-	Active	NO
17	U17110GJ1997PTC033436	SHAKTI POLYWEAVE PRIVATE LIMITED	Director	27/08/2009	01/10/2008	-	Active	NO
18	U40109MH2008PTC187793	FAMY ENERGY PRIVATE LIMITED	Director	27/10/2008	27/10/2008	-	Active	NO
19	U85110MH2008PTC187843	COMPLETE DIABETES CARE PRIVATE LIMITED	Director	29/10/2008	29/10/2008	03/10/2011	Active	NO
20	U80903MH2011PTC216683	INTEGRATED EDUTEAM SOLUTIONS PRIVATE LIMITED	Director	26/04/2011	26/04/2011	-	Active	NO

Name :

Mr. Ashutosh Jyotiprasad Taparia

Designation :

Managing Director

Address :

101/Laxmi Vilas, 10^th Floor, 87, Nepean Sea Road, Mumbai-400006, Maharashtra, India

Date of Birth/Age :

25.01.1973

Date of Appointment :

01.07.2010

Din No.:

00178771

Other Directorship :

S. No.	CIN/LLPIN	Name of the Company/ LLP	Current designation of the Director/ Designated Partner	Date of appointment at current designation	Original date of appointment	Date of cessation	Company/ LLP Status	Defaulting status
1	U01100MH1995PTC087949	MAKARAND PLANTATIONS PRIVATE LIMITED	Director	28/09/1996	28/09/1996	-	Active	NO
2	U01100MH1995PTC087946	GYAN PLANTATIONS PRIVATE LIMITED	Director	28/09/1996	28/09/1996	-	Active	NO
3	U25202MH1995PTC088387	FAMY STERI PRIVATE LIMITED	Director	13/11/1996	13/11/1996	-	Active	NO
4	U24236MH1987PLC044813	FAMY CARE LIMITED	Managing director	01/07/2010	10/09/1998	-	Active	NO
5	U51909MH2004PTC148478	PEEPAL TRADING AND AGENCIES PRIVATE LIMITED	Director	09/09/2004	09/09/2004	31/03/2008	Active	NO
6	U51909MH2004PTC148474	SILVA TRADING AND AGENCIES PRIVATE LIMITED	Director	09/09/2004	09/09/2004	31/03/2008	Active	NO
7	U24100GA2004PTC007040	ARYAVAAN PHARMACEUTICALS PRIVATE LIMITED	Director	29/09/2004	29/09/2004	16/03/2012	Active	NO
8	U45200MH2004PTC148885	SHUBH GRAH PRAVESH PRIVATE LIMITED	Director	29/09/2004	29/09/2004	-	Active	NO
9	U01100MH1995PTC087948	SAROJ PLANTATIONS PRIVATE LIMITED	Director	28/09/2006	28/09/2006	-	Active	NO
10	U51909MH2006PTC165687	SANGUINITY TRADING COMPANY PRIVATE LIMITED	Director	27/12/2006	27/12/2006	-	Active	NO
11	U24232GA1997PTC002374	BEACH HEALTHCARE PRIVATE LIMITED	Director	06/08/2007	06/08/2007	-	Active	NO
12	U24139MH2004PTC144395	TARAKESH PHARMA PRIVATE LIMITED	Director	30/09/2009	05/08/2008	-	Active	NO
13	U25190MH1998PTC114824	HEVEA FINE PRODUCTS PRIVATE LIMITED	Director	28/09/2009	05/08/2008	-	Active	NO
14	U17110GJ1997PTC033436	SHAKTI POLYWEAVE PRIVATE LIMITED	Director	27/08/2009	01/10/2008	-	Active	NO
15	U40109MH2008PTC187793	FAMY ENERGY PRIVATE LIMITED	Director	27/10/2008	27/10/2008	-	Active	NO
16	U85110MH2008PTC187843	COMPLETE DIABETES CARE PRIVATE LIMITED	Director	29/10/2008	29/10/2008	03/10/2011	Active	NO
17	U24232GA1997PTC002375	KENPACK PHARMA PRIVATE LIMITED	Director	12/01/2011	12/01/2011	-	Active	NO
18	U80903MH2011PTC216683	INTEGRATED EDUTEAM SOLUTIONS PRIVATE LIMITED	Director	26/04/2011	26/04/2011	-	Active	NO

Name :

Mr. Jyotiprasad Taparia

Designation :

Whole Time Director

Address :

101/Laxmi Vilas, 10^th Floor, 87, Nepean Sea Road, Mumbai-400006, Maharashtra, India

Date of Birth/Age :

21.11.1944

Date of Appointment :

01.04.2011

Din No.:

00157746

Other Directorship :

S. No.	CIN/LLPIN	Name of the Company/ LLP	Current designation of the Director/ Designated Partner	Date of appointment at current designation	Original date of appointment	Date of cessation	Company/ LLP Status	Defaulting status
1	U24236MH1987PLC044813	FAMY CARE LIMITED	Whole-time director	01/04/2011	28/09/1987	-	Active	NO
2	U01100MH1995PTC087946	GYAN PLANTATIONS PRIVATE LIMITED	Director	02/05/1995	02/05/1995	-	Active	NO
3	U01100MH1995PTC087948	SAROJ PLANTATIONS PRIVATE LIMITED	Director	10/05/1995	10/05/1995	-	Active	NO
4	U01100MH1995PTC087949	MAKARAND PLANTATIONS PRIVATE LIMITED	Director	10/05/1995	10/05/1995	-	Active	NO
5	U25202MH1995PTC088387	FAMY STERI PRIVATE LIMITED	Director	15/05/1995	15/05/1995	-	Active	NO
6	U24232GA1997PTC002375	KENPACK PHARMA PRIVATE LIMITED	Director	04/07/1997	04/07/1997	-	Active	NO
7	U51909MH2004PTC148478	PEEPAL TRADING AND AGENCIES PRIVATE LIMITED	Director	09/09/2004	09/09/2004	31/03/2008	Active	NO
8	U51909MH2004PTC148474	SILVA TRADING AND AGENCIES PRIVATE LIMITED	Director	09/09/2004	09/09/2004	31/03/2008	Active	NO
9	U24100GA2004PTC007040	ARYAVAAN PHARMACEUTICALS PRIVATE LIMITED	Director	29/09/2004	29/09/2004	16/03/2012	Active	NO
10	U45200MH2004PTC148885	SHUBH GRAH PRAVESH PRIVATE LIMITED	Director	29/09/2004	29/09/2004	-	Active	NO
11	U51909MH2006PTC165687	SANGUINITY TRADING COMPANY PRIVATE LIMITED	Additional director	10/04/2007	10/04/2007	-	Active	NO
12	U65993MH2000PTC128124	CARE INTEGRATED SERVICES PRIVATE LIMITED	Director	01/08/2007	01/08/2007	18/09/2007	Active	NO
13	U24232GA1997PTC002374	BEACH HEALTHCARE PRIVATE LIMITED	Director	06/08/2007	06/08/2007	-	Active	NO
14	L31300DN1961PLC000232	IMP POWERS LIMITED	Director	05/12/2008	23/01/2008	29/01/2010	Active	NO
15	U24139MH2004PTC144395	TARAKESH PHARMA PRIVATE LIMITED	Director	30/09/2009	05/08/2008	-	Active	NO
16	U25190MH1998PTC114824	HEVEA FINE PRODUCTS PRIVATE LIMITED	Director	28/09/2009	05/08/2008	-	Active	NO
17	U17110GJ1997PTC033436	SHAKTI POLYWEAVE PRIVATE LIMITED	Director	27/08/2009	01/10/2008	-	Active	NO
18	U40109MH2008PTC187793	FAMY ENERGY PRIVATE LIMITED	Director	27/10/2008	27/10/2008	-	Active	NO
19	U85110MH2008PTC187843	COMPLETE DIABETES CARE PRIVATE LIMITED	Director	29/10/2008	29/10/2008	03/10/2011	Active	NO
20	U80903MH2011PTC216683	INTEGRATED EDUTEAM SOLUTIONS PRIVATE LIMITED	Director	26/04/2011	26/04/2011	-	Active	NO
21	AAB-5890	EVERPLUS ESTATES LIMITED LIABILITY PARTNERSHIP	Body corporate as Designated Partner	18/06/2013	18/06/2013	-	Active	NO

Name :

Mr. Ajay Lal

Designation :

Director

Address :

Villa No. 120, The Laburnam, Sushant Lok-I, Gurgaon-122001, Haryana, India

Date of Birth/Age :

08.08.1961

Date of Appointment :

13.04.2010

Din No.:

00030388

Other Directorship :

S. No.	CIN/LLPIN	Name of the Company/ LLP	Current designation of the Director/ Designated Partner	Date of appointment at current designation	Original date of appointment	Date of cessation	Company/ LLP Status	Defaulting status
1	U74999AP1992PLC014388	GVK INDUSTRIES LIMITED	Director	23/10/2003	23/10/2003	26/07/2008	Active	NO
2	L65190MH2003PLC143249	YES BANK LIMITED	Nominee director	10/03/2004	10/03/2004	02/02/2007	Active	NO
3	U74140DL2005PTC142936	AIF CAPITAL (INDIA) PRIVATE LIMITED	Director	25/11/2005	25/11/2005	-	Active	NO
4	L74899DL1995PLC070609	BHARTI AIRTEL LIMITED	Director	21/08/2006	23/01/2006	-	Active	NO
5	L74999AP2005PLC059013	GVK POWER & INFRASTRUCTURE LIMITED	Director	22/05/2006	22/05/2006	21/08/2008	Active	NO
6	U27104GJ2003PLC043070	GPT STEEL INDUSTRIES LIMITED	Director	24/07/2006	24/07/2006	30/04/2008	Active	NO
7	U65191KL1920PLC000175	THE CATHOLIC SYRIAN BANK LTD	Director	15/09/2010	13/09/2007	-	Active	NO
8	U24232KA2004PTC033578	BIOPLUS LIFE SCIENCES PRIVATE LIMITED	Nominee director	06/06/2008	06/06/2008	-	Active	NO
9	U24236MH1987PLC044813	FAMY CARE LIMITED	Director	13/04/2010	13/04/2010	-	Active	NO

Name :

Barry Clare

Designation :

Director

Address :

55, Hampstead Way, London, England, Pin Code NWI17DP, United Kingdom

Date of Birth/Age :

25.06.1953

Date of Appointment :

31.12.2011

Din No.:

02442602

Other Directorship :

S. No.	CIN/LLPIN	Name of the Company/ LLP	Current designation of the Director/ Designated Partner	Date of appointment at current designation	Original date of appointment	Date of cessation	Company/ LLP Status	Defaulting status
1	U24232KA2004PTC033578	BIOPLUS LIFE SCIENCES PRIVATE LIMITED	Director	30/06/2008	30/06/2008	09/05/2011	Active	NO
2	U24236MH1987PLC044813	FAMY CARE LIMITED	Director	31/12/2011	31/12/2011	-	Active	NO

Name :

Mr. Ajay Kumar Vij

Designation :

Director

Address :

H. No. L-2, Sarita Vihar, New Delhi-110044, India

Date of Birth/Age :

28.09.1960

Date of Appointment :

31.12.2011

Din No.:

00164984

Other Directorship :

S. No.	CIN/LLPIN	Name of the Company/ LLP	Current designation of the Director/ Designated Partner	Date of appointment at current designation	Original date of appointment	Date of cessation	Company/ LLP Status	Defaulting status
1	L24231DL2003PLC119441	FRESENIUS KABI ONCOLOGY LIMITED	Director	07/07/2003	07/07/2003	08/08/2008	Active	NO
2	U73100DL1979NPL010092	DABUR RESEARCH FOUNDATION	Director	30/09/2008	04/09/2008	-	Active	NO
3	U33110DL2008PLC185857	ALTHEA LIFESCIENCES LIMITED	Whole-time director	07/09/2009	16/12/2008	-	Active	NO
4	U74900DL2009PTC195614	ASIA PACIFIC HEALTHCARE ADVISORS PRIVATE LIMITED	Director	30/10/2009	30/10/2009	-	Active	NO
5	U85110DL2005PTC133331	DIWAN CHAND MEDICAL SERVICES PRIVATE LIMITED	Director	29/09/2010	11/03/2010	-	Active	NO
6	U85110DL2005PTC136057	DIWAN CHAND RADNET SERVICES PRIVATE LIMITED	Director	29/09/2010	11/03/2010	-	Active	NO
7	U85110DL2001PTC112923	DIWAN CHAND INTEGRAL HEALTH SERVICES PRIVATE LIMITED	Director	29/09/2010	11/03/2010	-	Active	NO
8	U24236MH1987PLC044813	FAMY CARE LIMITED	Director	31/12/2011	31/12/2011	-	Active	NO
9	U33112MH2010PTC209530	TOTAL DENTAL CARE PRIVATE LIMITED	Nominee director	08/04/2013	08/04/2013	-	Active	NO

MAJOR SHAREHOLDERS / SHAREHOLDING PATTERN

AS ON 11.12.2012

Names of Shareholders	No. of Shares
Jyotiprasad K. Taparia	129450
Urmiladevi J. Taparia	280750
Ashutosh J. Taparia	247600
Jyotiprasad K. Taparia (HUF)	183000
Sanjiv J. Taparia	219250
Aruna S. Taparia	128500
Anjali S. Taparia	30000
Nidhi S. Taparia	30000
Anjali S. Taparia	160000
Orizaba Limited, Mauritius	298780
TOTAL	1707330

AS ON 11.12.2012

Equity Share Breakup	Percentage of Holding
Category
Foreign holdings [Foreign institutional investors, Foreign Companies, Foreign Financial Institutions, Non-resident Indian or Overseas corporate bodies or others]	17.50
Directors or relatives of directors	82.50
TOTAL	100.00

BUSINESS DETAILS

Line of Business :

Manufacturing, Selling and Development of Pharmaceutical Products.

PRODUCTION STATUS [AS ON 31.03.2011]

Particulars	Unit	Installed Capacity	Actual Production
Copper T	(Pcs. in Lacs)	195.00	29.37
Oral Contraceptive Pills	(OCP) (Cycles in Lacs)	5800.00	2495.69
Tubal Rings	(Pairs in Lacs)	300.00	2.17
Exacta	(Pep Smear Kit) (Pcs in Lacs )	25.00	0.002
Injectables	(Nos. in Lacs)	650.00	6.50

NOTE: Since the industrial licensing for Drugs and Pharmaceuticals has been abolished under the Industrial Policy, the particulars of licensed capacity are not stated.

GENERAL INFORMATION

No. of Employees :

Not Available

Bankers :

State Bank of India, Commercial Branch, N. G. N. Vaidya Marg, Mumbai – 400023, Maharashtra, India

Facilities :

Secured Loan	As on 30.06.2012 [Rs. in Millions]	As on 30.06.2011 [Rs. in Millions]
Loans repayable on demand from banks	254.798	44.720
TOTAL	254.798	44.72

Banking Relations :	--
Auditors :
Name :	S R Batliboi and Company Chartered Accountants
Address :	14th Floor, The Ruby 2 9 , Senapati Bapat Marg, Dadar (West), Mumbai-400028, Maharashtra, India
PAN No:	AALFS0506L
Subsidiaries :	· Hevea Fine Products Private Limited [U25190MH1998PTC114824] · Tarakesh Pharma Private Limited [U24139MH2004PTC144395] · Famy Care Europe Limited · Famy Care Peru S.R.L
Joint Venture :	· Essential Drugs Private Limited [U85100DL2009PTC188867] · PharmaGen LLC (w.e.f. 24th August 2011)
Other Related Parties :	· Famy Energy Private Limited [U40109MH2008PTC187793] · Vastu Shining Private Limited (Till March 2012)

CAPITAL STRUCTURE

AS ON 30.06.2012

Authorised Capital :

No. of Shares	Type	Value	Amount
12000000	Equity Shares	Rs.10/- each	Rs.120.000 Millions

Issued, Subscribed & Paid-up Capital :

No. of Shares	Type	Value	Amount
1707330	Equity Shares	Rs.10/- each	Rs.17.073 Millions

FINANCIAL DATA

[all figures are in Rupees Millions]

ABRIDGED BALANCE SHEET

SOURCES OF FUNDS		30.06.2012	30.06.2011	30.06.2010
SHAREHOLDERS FUNDS
1] Share Capital		17.073	17.073	17.073
2] Share Application Money		0.000	0.000	0.000
3] Reserves & Surplus		2364.224	2189.372	3790.246
4] (Accumulated Losses)		0.000	0.000	0.000
NETWORTH		2381.297	2206.445	3807.319
LOAN FUNDS
1] Secured Loans		254.798	44.720	222.255
2] Unsecured Loans		0.000	0.000	0.000
TOTAL BORROWING		254.798	44.720	222.255
DEFERRED TAX LIABILITIES		0.000	0.000	17.000
TOTAL		2636.095	2251.165	4046.574
APPLICATION OF FUNDS
FIXED ASSETS [Net Block]		818.692	848.669	907.153
Capital work-in-progress		43.146	9.601	0.000
INVESTMENT		919.832	320.478	2018.055
DEFERREX TAX ASSETS		0.908	7.296	0.000
CURRENT ASSETS, LOANS & ADVANCES
	Inventories	234.033	221.593	172.408
	Sundry Debtors	941.519	967.215	979.280
	Cash & Bank Balances	26.922	57.999	30.726
	Other Current Assets	144.316	2.647	0.000
	Loans & Advances	373.510	212.673	544.686
Total Current Assets		1720.300	1462.127	1727.100
Less : CURRENT LIABILITIES & PROVISIONS
	Sundry Creditors	205.594	147.099	180.485
	Other Current Liabilities	458.091	83.301	185.967
	Provisions	203.098	166.606	239.282
Total Current Liabilities		866.783	397.006	605.734
Net Current Assets		853.517	1065.121	1121.366
MISCELLANEOUS EXPENSES		0.000	0.000	0.000
TOTAL		2636.095	2251.165	4046.574

PROFIT & LOSS ACCOUNT

	PARTICULARS		30.06.2012	30.06.2011	30.06.2010
	SALES
		Income	2206.549	2026.068	2579.657
		Other Income	96.030	18.724	41.852
		TOTAL (A)	2302.579	2044.792	2621.509
Less	EXPENSES
		Cost of materials consumed	307.299	359.577
		Purchases of stock-in-trade	166.934	40.562
		Employee benefit expense	314.938	265.653
		Other expenses	644.754	478.368	1700.123
		Prior period items	0.000	140.105
		Changes in inventories of finished goods, work-in-progress and stock-in-trade	43.453	(18.243)
		TOTAL (B)	1477.378	1266.022	1700.123
Less	PROFIT / (LOSS) BEFORE INTEREST, TAX, DEPRECIATION AND AMORTISATION (A-B) (C)		825.201	778.770	921.386
Less	FINANCIAL EXPENSES (D)		12.970	8.930	20.121
	PROFIT / (LOSS) BEFORE TAX, DEPRECIATION AND AMORTISATION (C-D) (E)		812.231	769.840	901.265
Less/ Add	DEPRECIATION/ AMORTISATION (F)		114.822	124.203	125.830
	PROFIT / (LOSS) BEFORE TAX (E-F) (G)		697.409	645.637	775.435
Less	TAX (H)		138.860	60.265	113.177
	PROFIT / (LOSS) AFTER TAX (G-H) (I)		558.549	585.372	662.258
Add	PREVIOUS YEARS’ BALANCE BROUGHT FORWARD		2106.200	1865.000	1277.600
Less	APPROPRIATIONS
		Transfer to General Reserve	55.800	58.500	66.300
		Dividend	17.100	8.500	7.300
		Corporate Dividend Tax	2.800	1.400	1.200
		Transfer on Demerger	0.000	275.800	0.000
	BALANCE CARRIED TO THE B/S		2589.049	2106.172	1865.058
	EARNINGS IN FOREIGN CURRENCY
		Export Earnings	2052.100	1983.600	2073.000
	IMPORTS
		Raw Materials & Packing Material	NA	160.238	148.196
		Traded Goods	NA	28.895	234.234
		Capital Goods	NA	17.602	18.088
		Store & Spares	NA	5.710	3.667
	TOTAL IMPORTS		NA	212.445	404.185
	Earnings / (Loss) Per Share (Rs.)		327.25	342.86	452.04

KEY RATIOS

PARTICULARS		30.06.2012	30.06.2011	30.06.2010
PAT / Total Income	(%)	24.25	28.63	25.26
Net Profit Margin (PBT/Sales)	(%)	31.61	31.87	30.05
Return on Total Assets (PBT/Total Assets}	(%)	27.47	27.94	29.44
Return on Investment (ROI) (PBT/Networth)		0.29	0.29	0.20
Debt Equity Ratio (Total Debt/Networth)		0.11	0.02	0.05
Current Ratio (Current Asset/Current Liability)		1.98	3.68	2.85

LOCAL AGENCY FURTHER INFORMATION

Sr. No.	Check List by Info Agents	Available in Report (Yes / No)
1]	Year of Establishment	Yes
2]	Locality of the firm	Yes
3]	Constitutions of the firm	Yes
4]	Premises details	No
5]	Type of Business	Yes
6]	Line of Business	Yes
7]	Promoter's background	Yes
8]	No. of employees	No
9]	Name of person contacted	No
10]	Designation of contact person	No
11]	Turnover of firm for last three years	Yes
12]	Profitability for last three years	Yes
13]	Reasons for variation <> 20%	--
14]	Estimation for coming financial year	No
15]	Capital in the business	Yes
16]	Details of sister concerns	Yes
17]	Major suppliers	No
18]	Major customers	No
19]	Payments terms	No
20]	Export / Import details (if applicable)	No
21]	Market information	--
22]	Litigations that the firm / promoter involved in	--
23]	Banking Details	Yes
24]	Banking facility details	Yes
25]	Conduct of the banking account	--
26]	Buyer visit details	--
27]	Financials, if provided	Yes
28]	Incorporation details, if applicable	Yes
29]	Last accounts filed at ROC	Yes
30]	Major Shareholders, if available	Yes
31]	PAN of Proprietor/Partner/Director, if available	No
32]	Date of Birth of Proprietor/Partner/Director, if available	Yes
33]	Voter ID No of Proprietor/Partner/Director, if available	No
34]	External Agency Rating, if available	Yes

INDEX OF CHARGES:

S. No.	Charge ID	Date of Charge Creation/Modification	Charge amount secured	Charge Holder	Address	Service Request Number (SRN)
1	10182650	27/12/2010 *	1,025,000,000.00	STATE BANK OF INDIA	COMMERCIAL BRANCH (ADVANCES), N.G.N. VAIDYA MARG, MUMBAI - 400023, MAHARASHTRA, INDIA	B03043361
2	10134730	26/12/2008	375,000,000.00	3I INFOTECH TRUSTEESHIP SERVICES LIMITED	3RD TO 6TH FLOOR, INTERNATIONAL INFOTECH PARK, TOWER NO.5, VASHI RAILWAY STATION COMPLEX, VASHI, NAVI MUMBAI - 400703, MAHARASHTRA, INDIA	A53321691
3	10125648	15/10/2008	150,000,000.00	THE HONGKONG AND SHANGHAI BANKING CORPORATION LIMI TED	52/60, MAHATAMA GANDHI ROAD, FORT, MUMBAI - 400001, MAHARASHTRA, INDIA	A47815204
4	10071191	31/08/2007	53,800,000.00	STATE BANK OF INDIA	COMMERCIAL BRANCH, N.G.N. VAIDYA MARG, FORT, MUMBAI - 400023, MAHARASHTRA, INDIA	A25015058
5	10063966	02/06/2010 *	450,000,000.00	HDFC BANK LIMITED	HDFC BANK HOUSESENAPATI BAPAT MARG, LOWER PAREL W, MUMBAI - 400013, MAHARASHTRA, INDIA	A89344063
6	10030017	11/02/2010 *	300,000,000.00	STANDARD CHARTERED BANK	90, M G ROAD, FORT, MUMBAI - 400001, MAHARASHTRA, INDIA	A81512220
7	90210971	29/03/1999	35,000,000.00	STATE BANK OF INDIA	COMMERCIAL BRANCH, JUSTICE G.N. VAIDYA MARG, MUMBAI - 400023, MAHARASHTRA, INDIA	-
8	90212974	10/01/1997	35,000,000.00	ICICI LIMITED	163; BACKBAY RECLAMATION, MUMBAI - 400020, MAHARASHTRA, INDIA	-
9	90210887	20/02/1996	98,500,000.00	STATE BANK OF INDIA	COMMERCIAL BRANCH, JUSTICE G.N. VAIDYA MARG, MUMBAI - 400023, MAHARASHTRA, INDIA	-
10	90212796	24/03/1999 *	35,000,000.00	ICICI LIMITED	163; BACKBAY RECLAMATION, MUMBAI - 400020, MAHARASHTRA, INDIA	-
* Date of charge modification

REVIEW OF OPERATIONS:

The Company has reported satisfactory performance for the year against the background turbulent global business outlook. The Profit after Tax has declined marginally from Rs. 585.400 millions to Rs. 558.500 millions mainly due to MAT applicable for SEZ unit. The Company has achieved a turnover of Rs. 2206.500 millions (Previous Year Rs. 2026.100 millions) including Product Development Charges/Dossier Revenue of Rs.223.100 millions (Previous Year Rs. 507.700 millions). The Company has successfully executed all the orders received from various customers, during the year.

Further, the Company has successfully filed 36 Abbreviated New Drug Application (ANDA) with USFDA till date. The products are being developed under an Agreement with Mylan Pharmaceuticals Inc. wherein the products will be marketed by them under Exclusive Marketing Arrangement for USA other than NGO market in US. The Company has also filed 9 dossiers with Health Canada (TPD) in Canada and has filed Dossier for 9 products with European Health Authorities till date. The Company has entered into Marketing Arrangement with leading pharmaceutical companies for European and Russian Market.

The Company has signed Technical Collaboration Agreement with Axar Pharmaceutical Inc for development of Non Contraceptive Products. The Company has committed USD eleven million for the development of the Non Oral Contraceptive Products, out of which an amount not exceeding USD six million is proposed to be spent until June'2013 and balance USD five million until June'2014. The Non Oral Contraceptive Products which will be developed under the Technical Collaboration Agreement with Axar Pharmaceutical Inc are expected to contribute significantly to the top line and bottom line of the Company in the coming years.

The Company has launched two products in European market during the year. The company has entered into Long Term Agreements for three years with UNFPA for businesses in the Rest of the World Market (other than US and Europe Markets) as of November'2012 as the company has received the WHO (World Health Organization) prequalification.

FUTURE PLANS:

The Company has made good progress in its plan to enter into Regulated Market of United States of America (U.S.A.), Canada and Europe.

During the year, US FDA audit was completed for both the units of the company located at Sarigam and Ahmadabad in the month of June'2012. Subsequently the company received the audit clearance report from USFDA for the Sarigam facility in the month of November'2012. The approval of Ahmadabad facility is expected in near future. The commercial launch of products in US/Canada Market is expected in the first quarter of calendar year 2013.

The Company plans to launch 3 more products in European market before end of current financial year. The company plans to file 2 ANDA for registration with USFDA for US markets, 2 ANDA's with Health Canada (TPD) in Canada and Dossier for 4 products with Drug Authorities in European Countries in the current financial year

The Research and Development Team of the Company is working on Injectable Contraceptives, New Drug Delivery System (NDDS) in Contraceptives which has good potential in international market. The Company is also developing Anti�Malarial Product and Ophthalmic Products.

FIXED ASSETS:

· Leasehold Land

· Building

· Plant and Machinery

· Laboratory Equipment

· Vehicles

· Office Equipment

· Furniture and Fixtures

NEWS:

FAMY CARE RECEIVES US FDA APPROVAL FOR GENERIC NORDETTE 28 TABLETS

PITTSBURGH

MONDAY, DECEMBER 31, 2012, [IST]

The US Food and Drug Administration (FDA) has granted final approval for Famy Care's Abbreviated New Drug Application (ANDA) for levonorgestrel and ethinyl estradiol tablets USP, 0.15 mg/0.03 mg. This product is the generic version of Teva Branded Pharmaceutical Products' Nordette 28 tablets, which are indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception.

The product will be distributed in the US by Mylan Pharmaceuticals Inc., and the company is shipping product immediately.

Heather Bresch, CEO, Mylan said, "The approval and immediate launch of our levonorgestrel and ethinyl estradiol tablets USP, 0.15 mg/0.03 mg, represents an exciting advance for the women's health care franchise that Mylan is establishing in partnership with Famy Care Ltd., one of the world's largest manufacturers of oral contraceptives. Presently, we have 34 oral contraceptives pending approval with the FDA and expect to receive additional approvals of these products beginning in next year's first quarter."

Levonorgestrel and ethinyl estradiol tablets USP, 0.15 mg/0.03 mg, had US sales of approximately $60.4 million for the 12 months ending Sept. 30, 2012, according to IMS Health.

Currently, Mylan has 185 ANDAs pending FDA approval representing $80.6 billion in annual sales, according to IMS Health. Thirty-five of these pending ANDAs are potential first-to-file opportunities, representing $21.2 billion in annual brand sales, for the 12 months ending June 30, 2012, according to IMS Health.

Mylan is a global pharmaceutical company committed to setting new standards in health care.

CMT REPORT (Corruption, Money Laundering & Terrorism]

The Public Notice information has been collected from various sources including but not limited to: The Courts, India Prisons Service, Interpol, etc.

1] INFORMATION ON DESIGNATED PARTY

No exist designating subject or any of its beneficial owners, controlling shareholders or senior officers as terrorist or terrorist organization or whom notice had been received that all financial transactions involving their assets have been blocked or convicted, found guilty or against whom a judgement or order had been entered in a proceedings for violating money-laundering, anti-corruption or bribery or international economic or anti-terrorism sanction laws or whose assets were seized, blocked, frozen or ordered forfeited for violation of money laundering or international anti-terrorism laws.

2] Court Declaration :

No exist to suggest that subject is or was the subject of any formal or informal allegations, prosecutions or other official proceeding for making any prohibited payments or other improper payments to government officials for engaging in prohibited transactions or with designated parties.

3] Asset Declaration :

No records exist to suggest that the property or assets of the subject are derived from criminal conduct or a prohibited transaction.

4] Record on Financial Crime :

Charges or conviction registered against subject: None

5] Records on Violation of Anti-Corruption Laws :

Charges or investigation registered against subject: None

6] Records on Int’l Anti-Money Laundering Laws/Standards :

Charges or investigation registered against subject: None

7] Criminal Records

No available information exist that suggest that subject or any of its principals have been formally charged or convicted by a competent governmental authority for any financial crime or under any formal investigation by a competent government authority for any violation of anti-corruption laws or international anti-money laundering laws or standard.

8] Affiliation with Government :

No record exists to suggest that any director or indirect owners, controlling shareholders, director, officer or employee of the company is a government official or a family member or close business associate of a Government official.

9] Compensation Package :

Our market survey revealed that the amount of compensation sought by the subject is fair and reasonable and comparable to compensation paid to others for similar services.

10] Press Report :

No press reports / filings exists on the subject.

CORPORATE GOVERNANCE

MIRA INFORM as part of its Due Diligence do provide comments on Corporate Governance to identify management and governance. These factors often have been predictive and in some cases have created vulnerabilities to credit deterioration.

Our Governance Assessment focuses principally on the interactions between a company’s management, its Board of Directors, Shareholders and other financial stakeholders.

CONTRAVENTION

Subject is not known to have contravened any existing local laws, regulations or policies that prohibit, restrict or otherwise affect the terms and conditions that could be included in the agreement with the subject.

FOREIGN EXCHANGE RATES

Currency	Unit	Indian Rupees
US Dollar	1	Rs.66.57
UK Pound	1	Rs.103.34
Euro	1	Rs.88.16

INFORMATION DETAILS

Report Prepared by :

TPT

SCORE & RATING EXPLANATIONS

SCORE FACTORS	RANGE	POINTS
HISTORY	1~10	7
PAID-UP CAPITAL	1~10	7
OPERATING SCALE	1~10	6
FINANCIAL CONDITION
--BUSINESS SCALE	1~10	6
--PROFITABILIRY	1~10	6
--LIQUIDITY	1~10	7
--LEVERAGE	1~10	7
--RESERVES	1~10	7
--CREDIT LINES	1~10	6
--MARGINS	-5~5	-
DEMERIT POINTS
--BANK CHARGES	YES/NO	YES
--LITIGATION	YES/NO	NO
--OTHER ADVERSE INFORMATION	YES/NO	NO
MERIT POINTS
--SOLE DISTRIBUTORSHIP	YES/NO	NO
--EXPORT ACTIVITIES	YES/NO	NO
--AFFILIATION	YES/NO	YES
--LISTED	YES/NO	NO
--OTHER MERIT FACTORS	YES/NO	YES
--RBI	YES/NO	NO
--EPF	YES/NO	NO
TOTAL		59

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

Financial condition (40%) Ownership background (20%) Payment record (10%)

Credit history (10%) Market trend (10%) Operational size (10%)

RATING EXPLANATIONS

RATING		STATUS	PROPOSED CREDIT LINE
>86	Aaa	Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums	Unlimited
71-85	Aa	Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums	Large
56-70	A	Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums	Fairly Large
41-55	Ba	Overall operation is considered normal. Capable to meet normal commitments.	Satisfactory
26-40	B	Capability to overcome financial difficulties seems comparatively below average.	Small
11-25	Ca	Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity	Limited with full security
<10	C	Absolute credit risk exists. Caution needed to be exercised	Credit not recommended
-	NB	New Business	-

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.